Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Absolute Bioavailability of Tebapivat in Healthy Men
NCT06745271Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tebapivat in sickle cell disease (SCD), myelodysplastic syndrome (MDS) and pyruvate kinase deficiency (PKD), sponsored by Agios Pharmaceuticals. Primary endpoints: Percentage of Radioactive Dose Excreted in Urine Over a Time Interval (feut1-t2) of [14C]-Tebapivat, Percentage of Radioactive Dose Excreted in Feces Over a Time Interval (fef t1-t2) of [14C]-Tebapivat and 12 more. Started Dec 2024; status: completed.
02
Drugs
tebapivat
03
Conditions
sickle cell disease (SCD)myelodysplastic syndrome (MDS)pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT06745271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745271.